Baron Health Care Fund: Q3 2026 New Positions And Exits

The Fund added 4 positions and exited 14 during the quarter, ending with 33 positions. It initiated a position in Biogen, which it believes is in the early stages of a transformation, and sold Madrigal Pharmaceuticals to manage risk ahead of a competitor’s clinical trial readout.

Analysis

This is a manager-positioning signal, not evidence of a change in either company’s fundamentals. The BIIB “transformation” thesis is untestable from the disclosure: the key issue is whether new products or pipeline assets can offset pressure on legacy revenue, and on what timeline. Until asset-level uptake, trial milestones, and guidance support that bridge, the claim should not justify paying for a re-rating. For MDGL, exiting ahead of an unnamed competitor readout highlights binary catalyst risk, but does not establish that the readout threatens Madrigal’s clinical or commercial outlook. Avoid inferring the competitor or its likely result.

Near term, expect limited information value absent position sizes or subsequent company disclosures. Over 1–3 months, monitor the competitor’s readout and any BIIB trial, regulatory, or commercial data that can validate the transformation thesis. Over 6–18 months, the relative outcome depends on execution and whether new revenue streams can replace any erosion in established products; a portfolio manager’s entry alone is not confirmation. The contrarian point is that the disclosure may invite investors to trade a vague BIIB turnaround and an unspecified MDGL overhang as if either were a fundamental catalyst. Neither thesis is sufficiently specified here.

Key Decisions for Investors

• No immediate trade from this disclosure alone. Do not treat the BIIB initiation as an independent signal without the fund’s position size, valuation basis, and identified transformation drivers.
• For BIIB, keep on a catalyst watchlist rather than adding on the narrative: verify asset-level sales or adoption, clinical milestones, and guidance evidence that new products can offset legacy-product pressure. Reassess if execution data fail to support that bridge.
• For MDGL, avoid an event-driven short based solely on the manager’s risk reduction. Identify the unnamed competitor and readout date, then assess endpoint relevance and implications for Madrigal before positioning; a benign or delayed readout would weaken the overhang thesis.
• A BIIB–MDGL pair is not supported by the available information: the disclosure gives no relative valuation, exposure, or catalyst probabilities. Revisit only when those inputs and the relevant trial data are verifiable.